Cutler Group LP Mersana Therapeutics, Inc. Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$8.56 - $14.47 $39,376 - $66,562	-4,600 Reduced 79.31%	1,200 $11,000
Q2 2021 Jul 19, 2021	BUY	$13.28 - $18.07 $29,216 - $39,754	2,200 Added 61.11%	5,800 $78,000
Q1 2021 Apr 26, 2021	BUY	$15.31 - $26.52 $41,337 - $71,604	2,700 Added 300.0%	3,600 $58,000
Q3 2020 Oct 27, 2020	BUY	$16.2 - $25.7 $11,340 - $17,990	700 Added 350.0%	900 $16,000
Q1 2020 May 07, 2020	BUY	$4.41 - $9.28 $882 - $1,855	200 New	200 $1,000

126

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $57.3M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.